What’s new in lung cancer

   Rated 0 / 5 stars

Save

CPD for this activity

Educational Activities (EA)

0.5 hours

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

Reviewing Performance (RP)

0.5 hours

These are activities that require reflection on feedback about your work.

Measuring Outcomes (MO)

0 hours

These are activities that use your work data to ensure quality results.

EA
0.5 mins

Educational Activities (EA)
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

RP
0.5 mins

Reviewing Performance (RP)
These are activities that require reflection on feedback about your work.

MO
0 mins

Measuring Outcomes (MO)
These are activities that use your work data to ensure quality results.

Listen to the episode

Description

In this Healthed lecture, Prof Michael Boyer AM, explains that lung cancer is the leading cause (19%) of cancer deaths in Australia, and 15% occur in non-smokers. Prof Boyer covers a number of key developments in this field that are relevant to primary care: Screening has been shown to work and this allows the use of new strategies for the management of early disease such as minimally invasive surgery and precision radiotherapy.

Prof Boyer also explains how the screening guidelines can work in primary care. Immunotherapy can be a game-changer for the treatment of locally advanced disease as well as metastatic disease because it improves cure rate and survival. It’s important to understand the novel side effects and other features of this relatively new modality.

Last Updated: 22 Jun, 2022

Rate this podcast
Help your colleagues find podcasts they'll enjoy by rating this podcast out of five stars.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Fiona Chan

Dr Fiona Chan

Multiple Sclerosis vs Antibody Disease – What GPs Need to Know

Prof Andrew Sindone & Dr Ted Wu

Prof Andrew Sindone & Dr Ted Wu

Using SGLT2 to Reduce Cardiovascular Death in T2D – Important Updates for GPs

Prof Rod Baber

Prof Rod Baber

Menopause and MHT: Maximising Benefits & Minimising Risks

Dr Shannon Thomas

Dr Shannon Thomas

Peripheral Arterial Disease

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Michael Boyer AM

expert

Prof Michael Boyer AM

Medical Oncologist; Chief Clinical Officer, Chris O’Brien Lifehouse

Recent articles

Find your area of interest

Share this

You have completed the Educational Activities (EA) component of this activity.

Select ‘Confirm & claim CPD‘ to confirm you have engaged with this activity in its entirety and claim your CPD.

You will be taken to explore further CPD learning available to you.

Menopause and MHT

Multiple sclerosis vs antibody disease

Using SGLT2 to reduce cardiovascular death in T2D

Peripheral arterial disease